Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.

Breast Cancer · 2022 · PMC8421464 · PMID 34491513

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Many of the QoL constituent domains showed a positive trend with low-dose nab-PTX, but SFWB showed the opposite trend, for unknown reasons.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.